Thompson Davis & Co’s Mentari Therapeutics, Inc. Common Stock MTRI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
– Sell
-1,025
Closed -$22.4K – 171
2025
Q3
$22.4K Buy
+1,025
New +$24.7K 0.01% 145

Other funds holding MTRI

Thompson Davis & Co's MTRI Position: Q4 2025 in Review

Thompson Davis & Co sold out of Mentari Therapeutics, Inc. Common Stock (MTRI) in Q4 2025, closing a stake of 1,025 shares — an estimated $22.4K sold.

Thompson Davis & Co first reported a position in MTRI in Q3 2025 and held it in 1 quarter. The position peaked at $22.4K in Q3 2025. 6 funds tracked by Wall St. Rank hold MTRI as of Q4 2025.

  • Thompson Davis & Co reported no remaining Mentari Therapeutics, Inc. Common Stock position as of Q4 2025 after selling out during the quarter.
  • Thompson Davis & Co sold 1,025 Mentari Therapeutics, Inc. Common Stock shares in Q4 2025, an estimated $22.4K.
  • Thompson Davis & Co first reported a position in Mentari Therapeutics, Inc. Common Stock in Q3 2025 and held it in 1 quarter.
  • Thompson Davis & Co's Mentari Therapeutics, Inc. Common Stock position peaked at $22.4K in Q3 2025.
  • 6 funds tracked by Wall St. Rank held Mentari Therapeutics, Inc. Common Stock as of Q4 2025.

Based on Thompson Davis & Co's 13F filing for Q4 2025, filed 12 Jan 2026.